SCHEMBL4827313

SCHEMBL4827313

CNC(C)c1cc(F)cc(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
SLC6A4 P31645 5/20 0.34
HTR2A P28223 2/20 0.34
KCNH2 Q12809 2/20 0.34
SLC6A3 Q01959 4/20 0.33
PARP14 Q460N5 1/20 0.33
PDPK1 O15530 1/20 0.33
RPS6KB1 P23443 1/20 0.33
CYP2D6 P10635 4/20 0.33
CYP3A4 P08684 3/20 0.33
SLC6A2 P23975 3/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA9 Q16790 1/20 0.32
IDO1 P14902 1/20 0.31
TDO2 P48775 1/20 0.31
ATP1A1 P05023 1/20 0.31
ATP1B1 P05026 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17790211 1.00 ALDH1A1 (0.36) ALDH1A1CES2CES1SLC6A4HTR2A
SCHEMBL4827316 1.00 ALDH1A1 (0.36) ALDH1A1CES2CES1SLC6A4HTR2A
SCHEMBL4835331 0.85 HTR2A (0.40) ALDH1A1SLC6A4HTR2AKCNH2PARP14
SCHEMBL31226791 0.85 ALDH1A1 (0.35) ALDH1A1SLC6A4HTR2AKCNH2PARP14
SCHEMBL4835323 0.85 HTR2A (0.40) ALDH1A1SLC6A4HTR2AKCNH2PARP14
SCHEMBL15211633 0.82 SOS1 (0.39) SLC6A4HTR2AKCNH2
SCHEMBL19354872 0.82 SOS1 (0.39) SLC6A4HTR2AKCNH2
SCHEMBL17233115 0.82 SOS1 (0.39) SLC6A4HTR2AKCNH2
SCHEMBL13573700 0.80 CES2 (0.34) CES2CES1SLC6A3PDPK1RPS6KB1
SCHEMBL765625 0.78 CES2 (0.36) ALDH1A1CES2CES1SLC6A4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021055326-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 WO disclosed
EP-3016951-B1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-05-31 EP disclosed
US-9458110-B2 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-04 US disclosed
US-20160152628-A1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-06-02 US disclosed
US-20160016910-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS BRISTOL-MEYERS SQUIBB COMPANY (US) 2016-01-21 US disclosed
US-9126944-B2 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-09-08 US disclosed
US-20140243338-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed
US-8124634-B2 CB1 receptor modulators 7TM PHARMA A/S (DK) 2012-02-28 US disclosed
US-20100010061-A1 CB1 RECEPTOR MODULATORS 7TM PHARMA A/S (DK) 2010-01-14 US disclosed
US-7442692-B2 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2008-10-28 US disclosed
EP-1707564-B1 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-09-12 EP disclosed
US-20060223830-A1 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2006-10-05 US disclosed
EP-1707564-A2 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2006-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152628-A1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS MYLK, MYLK2, ROCK1 ALDH1A1 3223/4885CES2 4099/4885CES1 1976/4885
US-20060223830-A1 Indanyl-piperazine compounds HTR4, NR4A1, NR4A3 ALDH1A1 614/4885CES2 2363/4885CES1 2576/4885
US-20140243338-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS ROCK1, ROCK2, MYLK ALDH1A1 2675/4885CES2 4510/4885CES1 1868/4885
US-20100010061-A1 CB1 RECEPTOR MODULATORS CNR1, CNR2, GPR6 ALDH1A1 3325/4885CES2 500/4885CES1 312/4885
US-20160016910-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS ROCK1, ROCK2, MYLK ALDH1A1 2675/4885CES2 4510/4885CES1 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.